Biotech Breakout?
Executive Summary
1990 Value.... 722.1 1991 Value.... 1814.7 1992 Value.... 1586.7 1993 Value.... 1385.5 1994 Value.... 877.9 1995 Value.... 1529.2 1996 Value.... 1355.6 1997 Value.... 1377.5 1998 Value.... 2173.7 1999 Value.... 4313.1
You may also be interested in...
Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.
A Hundred Drugs Contend: Chinese Biopharma Gains US Foothold
Legend/J&J’s CAR-T cilta-cel and Chi-Med’s surufatinib would follow BeiGene’s Brukinsa, which won FDA approval in November 2019.